Apollomics (APLM) Total Liabilities (2021 - 2025)
Apollomics' (APLM) quarterly Total Liabilities came in at $7.0 million in Q4 2025, up 7256.84% year-over-year from $95000.0 in Q4 2024, and up 1425.98% quarter-over-quarter from $458000.0 in Q2 2025.
Analysis
Apollomics (APLM) Total Liabilities (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Total Liabilities for 5 consecutive years, with $7.0 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Total Liabilities rose 7256.84% year-over-year to $7.0 million in Q4 2025; TTM through Dec 2025 was $7.0 million, a 7256.84% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 7256.84% from the prior year.
- Total Liabilities was $7.0 million for Q4 2025 at Apollomics, up from $458000.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $448.1 million in Q4 2022 and troughed at $95000.0 in Q4 2024.
- A 5-year average of $121.4 million and a median of $7.0 million in 2025 frame the typical range for Total Liabilities.
- Across the five-year window, Total Liabilities slumped 99.94% in 2023 and jumped 7256.84% in 2025, its largest moves.
- Over 5 years, Total Liabilities stood at $322.2 million in 2021, then soared by 39.07% to $448.1 million in 2022, then tumbled by 99.94% to $259000.0 in 2023, then sank by 63.32% to $95000.0 in 2024, then jumped by 7256.84% to $7.0 million in 2025.
- The last three Total Liabilities figures came in at $7.0 million (Q4 2025), $458000.0 (Q2 2025), and $95000.0 (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | 6.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 6.99 Mn |
| Jun 30, 2025 | 458,000.00 |
| Dec 31, 2024 | 95,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Dec 31, 2023 | 259,000.00 |
| Jun 30, 2023 | 15.68 Mn |
| Dec 31, 2022 | 448.12 Mn |
| Jun 30, 2022 | 298.55 Mn |
| Dec 31, 2021 | 322.22 Mn |